Synchron Stock

synchron.comHealthcare / Medical DevicesFounded: 2016Funding to Date: $118.41MM

Synchron has developed an endovascular brain computer interface that can access every corner of the brain using its natural highways, the blood vessels. Their breakthrough platform launches a new frontier for the treatment of neurological diseases: Neurointerventional Electrophysiology (Neuro EP). This company was founded in 2016 and is headquartered in Brooklyn, NY.

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for Synchron, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Synchron’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Synchron.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Synchron investors also invested in these private companies


Management Team

Thomas Oxley Ph.D
Co-Founder, Chief Executive Officer & Board Member
Nicholas Opie Ph.D
Co-Founder, Chief Technology Officer & Board Member
Amos Meltzer
Chief Legal Officer
Rahul Sharma
Co-Founder & Board Member
J Mocco
Chief Medical Officer
Kurt Haggstrom
Chief Commercial Officer
Connie Rey
Vice President, Clinical Affairs
Gary Castro
Vice President, Finance
Riki Banerjee
Vice President, Research & Development

Board Members

Alexander Morgan Ph.D
Khosla Ventures
Ari Nowacek Ph.D
ARCH Venture Partners
Martin Dieck
NeuroTechnology Investors
Robert Nelsen
ARCH Venture Partners
Josh Duyan
Artisan Partners

Synchron’s stock FAQs


Can you buy Synchron’s stock?

As Synchron is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Synchron, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge's Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Synchron’s stock?

To invest in a private company like Synchron’s through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge's marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Synchron’s stock?

Yes, you may be able to sell your Synchron’s stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Synchron’s stock?

If you hold private company shares of Synchron’s - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Synchron’s on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Synchron’s a public company?

No, Synchron’s is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Synchron’s stock price?

Synchron is a privately held company and therefore does not have a public stock price. However, you may access Synchron’s private market stock price with Forge Data.

What is Synchron’s stock ticker symbol?

Synchron does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Brain implant patient says OpenAI’s tech helps him communicate with family

Synchron is using OpenAI's technology for its brain implant technology.

Synchron Launches Patient Registry for Stentrode Brain Computer Interface

The brain-computer interface technology company Synchron launched a community center for a BCI device to help patients with neurological conditions without the need for invasive brain surgery.

Synchron to start patient enrolment in brain-computer interface study

Synchron, an endovascular brain-computer interface (BCI) firm, has begun patient enrolment for its COMMAND study. The study will assess the safety and efficacy of the Synchron Switch, a BCI device that helps people with limited mobility operate technology using their thoughts. The device is implanted using a minimally-invasive procedure and the study will evaluate its impact on daily tasks such as texting, emailing, and online shopping.

Tom Oxley: translating thoughts into text with brain implants

Tom Oxley, a physician and entrepreneur, is developing an implantable brain-computer interface at his company, Synchron. The technology allows a patient's thoughts to be transmitted wirelessly through the skin to control digital devices. Oxley is a neurointerventionist at Mount Sinai Hospital and has performed over 1,600 endovascular neurosurgical procedures.
Updated on: Jul 25, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.